Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions
The authors discuss advanced sonocrystallization particle-engineering techniques for manufacturing mesoscopic particles.


Pharmaceutical Technology


Two mechanisms allow the crystal nuclei to form larger drug particles: the drug molecules in the organic phase diffuse toward the nuclei and condense, and the nuclei collide and coagulate together to form larger particles (16). At this stage, applied ultrasound plays a significant role in controlling the size of resulting particles. Although the particles can grow, predominantly by coagulation, ultrasound helps to deagglomerate and form submicrometer-sized crystalline particles. At high supersaturation, or a low particle-growth rate, submicrometer-sized particles can be produced. Because the concentration of the organic solvent in nonsolvent is extremely low, the particle growth through Ostwald ripening may be expected to be low relative to precipitation (17).

In all these dispersive crystallization methods, many parameters can influence particle characteristics and require optimization. They include ultrasonic power, concentration and feed rate of API solution, and temperature and flow rate of antisolvent. For emulsion crystallization, particle size is also governed by the interplay between dispersion, coagulation, deagglomeration, supersaturation, and Ostwald ripening (16, 17). The suspensions may be dried by common means such as supercritical carbon-dioxide extraction, spray drying, lyophilization, and centrifugation. Small-scale automated equipment can be used for designed studies to facilitate scale-up to the pilot plant.

Aerosolization, sonocrystallization, and SAX

Particle-engineering technology, especially techniques that control the production of microcrystalline particles with a narrow size distribution and overcome the disadvantages of common micronization techniques, has shown great promise in preparing particulate pharmaceuticals with defined physicochemical properties.

Techniques for producing drug particles include spray-drying, which involves generating an aerosol of droplets from a solution of the drug and subsequent drying of the droplets to solidify the particles. Spray-drying is one of the most widely used industrial processes involving particle formation and drying. It is highly suited for the continuous production of dry solids in either powder, granulate, or agglomerate form from, for example, liquid feedstocks such as solutions, emulsions, and suspensions. The end product of the spray-drying process should comply with quality standards for parameters such as particle-size distribution, residual moisture content, bulk density, and particle shape. A disadvantage of conventional spray-drying techniques is that the particles produced tend to be amorphous—perhaps as much as 100%—rather than in a crystalline particulate form because solidification is typically rapid.

Newer techniques offer greater control of crystallinity and morphology. To achieve optimal drug delivery to the lung, it is important to ensure that the drug is formulated into particles of the appropriate aerodynamic size, shape, and density.

Prosonix developed the SAX technology for preparing micro- and nanocrystalline particles for drug delivery and now seeks to industrialize the process. These particles are used principally for inhaled medicines for asthma and COPD as well as antibiotics (18). SAX and other sonocrystallization technologies could change the manufacturing of inhaled medicines significantly.

Multiple therapeutic areas

SAX is a scalable, economic technology that generally functions at ambient temperature and pressure (19–21). This solution-to-particle methodology avoids many of the problems apparent with the various methods available to date. Importantly, SAX also allows the production of spherical drug particles with unique nanotopology and superior aerodynamic properties. These characteristics improve the sorption characteristics by virtue of the increased particle surface area for a given size and volume.

SAX has been applied to many compounds to date, including new chemical entities (NCEs) and many steroidal compounds for asthma, COPD, and topical creams and gels. SAX has been used to prepare budesonide, fluticasone propionate, beclamethasone dipropionate, ciclesonide, betamethasone and mometasone furoate, -agonists for asthma and COPD, salmeterol xinafoate, formoterol fumarate, and salbutamol. Prosonix has also used SAX successfully for producing aminoglycoside and cephalosporin antibiotics.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
41%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here